Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Reported Tuberculosis in the United States, 2017										Related Pages
										Return to Main Menu
Table 44. Tuberculosis Cases and Percentages, by Initial Drug Regimen: Reporting Areas, 2017
Table 44. Tuberculosis Cases and Percentages, by Initial Drug Regimen: Reporting Areas, 2017
Reporting Area
Total Cases
Cases in Persons Alive at Diagnosis
Cases with Information on Initial Drug Regimen1
Percent of Cases in Persons with Initial Drug Regimen2No.
(%)
Multi 4+ Drug Regimen3
IRZE4United States
9,105
8,909
8,898
(99.9)
(10.2)
(83.2)Alabama
120
118
118
(100.0)
(12.7)
(84.7)Alaska
53
53
53
(100.0)
(1.9)
(92.5)Arizona
188
184
184
(100.0)
(4.3)
(93.5)Arkansas
85
85
84
(98.8)
(7.1)
(82.1)California
2,057
2,012
2,012
(100.0)
(8.4)
(86.0)Colorado
84
82
82
(100.0)
(6.1)
(76.8)Connecticut
63
61
61
(100.0)
(59.0)
(37.7)Delaware
15
15
15
(100.0)
(53.3)
(40.0)District of Columbia
36
34
34
(100.0)
(0.0)
(94.1)Florida
549
541
541
(100.0)
(7.4)
(87.1)Georgia
294
285
285
(100.0)
(56.8)
(35.4)Hawaii
116
115
115
(100.0)
(4.3)
(88.7)Idaho
10
10
10
(100.0)
(20.0)
(80.0)Illinois
335
324
324
(100.0)
(7.1)
(86.4)Indiana
100
100
100
(100.0)
(3.0)
(91.0)Iowa
47
46
46
(100.0)
(2.2)
(97.8)Kansas
29
28
28
(100.0)
(3.6)
(96.4)Kentucky
65
62
62
(100.0)
(11.3)
(83.9)Louisiana
141
139
137
(98.6)
(1.5)
(92.7)Maine
14
14
14
(100.0)
(21.4)
(71.4)Maryland
207
203
203
(100.0)
(11.8)
(86.7)Massachusetts
210
209
209
(100.0)
(12.4)
(84.2)Michigan
133
131
130
(99.2)
(3.8)
(93.1)Minnesota
178
177
177
(100.0)
(9.0)
(76.8)Mississippi
53
53
53
(100.0)
(3.8)
(75.5)Missouri
87
80
80
(100.0)
(11.3)
(83.8)Montana
3
3
3
(100.0)
(0.0)
(100.0)Nebraska
21
20
18
(90.0)
(27.8)
(66.7)Nevada
80
78
78
(100.0)
(2.6)
(96.2)New Hampshire
19
19
19
(100.0)
(21.1)
(68.4)New Jersey
284
279
276
(98.9)
(6.2)
(87.0)New  Mexico
37
34
32
(94.1)
(9.4)
(81.3)New York State5
193
191
191
(100.0)
(6.8)
(85.3)New York City
613
599
599
(100.0)
(10.7)
(84.3)North Carolina
213
207
207
(100.0)
(7.7)
(89.4)North Dakota
14
14
14
(100.0)
(28.6)
(71.4)Ohio
151
147
147
(100.0)
(15.6)
(79.6)Oklahoma
54
53
53
(100.0)
(17.0)
(69.8)Oregon
69
69
69
(100.0)
(7.2)
(88.4)Pennsylvania
192
181
181
(100.0)
(12.2)
(83.4)Rhode Island
13
12
12
(100.0)
(8.3)
(75.0)South Carolina
101
98
98
(100.0)
(20.4)
(73.5)South Dakota
14
12
12
(100.0)
(50.0)
(41.7)Tennessee
128
124
124
(100.0)
(5.6)
(91.9)Texas
1,127
1,104
1,104
(100.0)
(4.5)
(81.8)Utah
29
29
29
(100.0)
(0.0)
(96.6)Vermont
3
3
3
(100.0)
(0.0)
(100.0)Virginia
204
202
202
(100.0)
(4.0)
(95.5)Washington
207
204
204
(100.0)
(22.5)
(72.1)West Virginia
16
15
15
(100.0)
(0.0)
(86.7)Wisconsin
49
49
49
(100.0)
(14.3)
(83.7)Wyoming
2
2
2
(100.0)
(0.0)
(100.0)American Samoa6
2
2
2
(100.0)
(0.0)
(50.0)Fed. States of Micronesia6
143
143
143
(100.0)
(0.7)
(99.3)Guam6
84
83
82
(98.8)
(4.9)
(93.9)Marshall Islands6
187
183
183
(100.0)
(2.7)
(96.7)N. Mariana Islands6
36
36
36
(100.0)
(80.6)
(16.7)Puerto Rico6
40
37
37
(100.0)
(8.1)
(91.9)Republic of Palau6
20
20
20
(100.0)
(0.0)
(100.0)U.S. Virgin Islands6
0
0
0
...
...
...1Includes persons who were alive at diagnosis and did not have an unknown drug regimen.2Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District of Columbia).3Indicates at least a four drug regimen that is not IRZE only4I, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol. Cases with other drugs prescribed in addition to these drugs are excluded.5Excludes New York City.6Not included in U.S. totals.**Note:** Excluding cases with no information on drug regimen, 113 (1.3%) persons were not started on any drugs and 10 (0.1%) were started on one drug.
Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.
							
					
						Page last reviewed:  October 22, 2018					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue